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Introduction
Patients with atrial fi brillation have a 4 - to 5-fold 
increased risk of stroke due to embolism of throm-
bus in the left atrium [1]. Stroke risk varies depend-
ing on the presence or absence of several risk factors 
for cardiovascular disease [2,3], which were also used 
for creating a risk stratifi cation schemes for throm-
boembolism. Th e risk of thromboembolism is devided 
into low, intermediate, and high risk strata [4]. Given 
the limitations of oral anticoagulation treatment with 
vitamin K antagonists, such risk stratifi cation allows 
clinicians to target patients at “high risk” for treat-
ment with vitamin K antagonists. For the interme-
diate risk category, guidelines recommend treatment 
with vitamin K antagonists or aspirin, and aspirin is 
recommended for the low risk category. Schemes for 
stratifying the risk of stroke have been largely derived 
from non-anticoagulation arms of clinical trial co-
horts, in which many potential thromboembolic risk 
factors were not recorded. In these historical trials, 
less than 10% of patients screened were randomised, 
and over the past 15-20 years the evolution of risk 
schemes has not improved their predictive value for 
patients at high risk [5]. 
Clinical risk of stroke in atrial fi brillation
More recent data in patients at intermediate risk 
show that vitamin K antagonists are superior to as-
pirin in reducing the risk of thromboembolism and 
adverse events, [6-8] and aspirin does not reduce the 
risk of thromboembolism in atrial fi brillation patients 
at “low risk” [9]. Th us, a paradigm shift has been pro-
posed whereby greater eff orts are made to identify 
“truly low risk” patients who may not need any an-
tithrombotic treatment, whereas all others could be 
considered for oral anticoagulation [9-11]. 
Th e most widely used scheme for the risk of cardio 
embolic stroke includes the following criteria: Con-
gestive heart failure, Hypertension, Age ≥ 75 years, 
Diabetes mellitus, previous Stroke / Transient isch-
emic attack - CHADS2) [12]. Last two factors re-
double risk factors for thromboembolism. Many have 
discussed the limitations of this assessment because of 
the large proportion of patients with the moderate risk 
(11). In 2006, the guidelines by the American Society 
of Cardiology (American Heart Association - AHA) 
added another possible risk factors with less evidence, 
including female gender, age 65-74 years, coronary 
artery disease and thyrotoxicosis [13]. Th e additional 
risk factors could easily identify patients with truly 
low risk. Th erefore, they have been expressed in the 
CHA2DS2-VASc: Congestive heart failure, Hyper-
tension, Age ≥ 75 years, Diabetes mellitus, Previous 
Stroke / transient ischemic attack, Vascular disease, 
Age 65-74 years, Sex category. An analysis of 121,280 
patients with atrial fi brillation has demonstrated that 
the risk of both scales, CHADS2 and CHA2DS2-
VASc was dependent from risk factors. Th e second 
scale has proven to be more valid for stroke prediction 
in patients categorised as being at low and intermedi-
ate risk by the CHADS2 scheme. Th is is clinically im-
portant, as many of the patients at low risk according 
to CHADS2 are not at “truly low risk” and treatment 
guidelines are not conclusive for those at intermedi-
ate risk. Th e risk associated with a specifi c risk score 
in both CHADS2 and CHA2DS2-VASc depends 
on the risk factors composing the score. CHA2DS2-
VASc performed better than CHADS2 in predicting 
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patients at high risk and can also be used to identify 
patients with non-valvular atrial fi brillation with a 
truly low risk of thromboembolism. [14,15,16]. 
Table 1. Risk stratifi cation scheme for cardioembolic stroke 
in patients with atrial fi brillation according the CHADS2 
[15] 
Condition Points
C Congestive heart failure 1
H Hypertension 1
A Age >75 years 1
D Diabetes mellitus 1
S2 Previous Stroke / transient ischemic attack ≥2
Table 2. Risk stratifi cation scheme for cardioembolic stroke in 
patients with atrial fi brillation according the CHA2DS2-
VASc [16]
Condition Points
Congestive heart failure 1
Hypertension* 1
Age ≥75 years 2
Age 65-74 years 1
Previous Stroke / transient ischemic attack 2
Vascular diseases (myocardial infarction, pe-




*History of hypertension 
Patients with a certain risk factor or patients on a 
scale CHA (2) DS (2)-Vasco reach one point or more 
are candidates for oral anticoagulation. Patients who 
are on a scale CHA(2)DS(2)-VASc do not reach one 
point, are a group of truly low-risk and require no an-
ticoagulant treatment. 
HAS-BLED SCORE
Despite extensive use of oral anticoagulation 
in patients with atrial fi brillation and the increased 
bleeding risk associated with such drugs use, no 
handy quantifi cation tool of assessing this risk exists. 
HAS-BLED (Hypertension, Abnormal Renal/Liver 
Function, Stroke, Bleeding History or Predisposition, 
Labile INR, Elderly, Drugs/Alcohol Concomitantly) 
score is a practical risk score to estimate the one-year 
risk for major bleeding (intracranial, hospitalization, 
haemoglobin drop >2g/L and/or transfusion) in a pa-
tients with atrial fi brillation.
Table 3. HAS-BLED* score assesses risk of major bleeding in 
atrial fi brillation patients [17]
Condition Points
H Hypertension (systolic pressure ≥ 160 
mm Hg)
1
A Abnormal renal/liver function 1
S Stroke 1
B Bleeding history or predisposition 1
L Labile INR 1
E Elderly (>65) 1
D Drugs/alcohol concomitantly) 1
*HAS-BLED – Hypertension, Abnormal Renal/Liver Function, 
Stroke, Bleeding History or Predisposition, Labile INR, Elderly, 
Drugs/Alcohol Concomitantly; INR – International Normalized 
Ratio. 
How to reduce stroke risk in atrial fi brillation 
patients?
Th erapeutic cardio version and rhythm control 
do not reduce stroke risk [18]. Also percutaneous left 
atrial occlusion is of unclear overall benefi t [19,20]. 
On the basis of consistent results from >12 random-
ized trials, anticoagulation is established as highly ef-
fi cacious for prevention of stroke and moderately ef-
fi cacious for reducing mortality [21]. 
Th irty-three randomized trials involving >60 000 
participants have compared various antithrombotic 
agents with placebo/control or with one another [21, 
22-24]. Treatment with adjusted-dose warfarin (tar-
get INR, range 2.0 to 3.0) provides the greatest pro-
tection against stroke [relative risk reduction (RRR) 
64%; 95% CI, 49% to 74%], virtually eliminating the 
excess number of ischemic strokes associated with 
atrial fi brillation if the intensity of anticoagulation 
is adequate and reducing all-cause mortality by 26% 
(95% CI, 3% to 23%) (Table 3) [21]. Aspirin off ers 
modest protection against stroke (RRR, 22%; 95% 
CI, 6% to 35%). Th ere are no convincing data that 
favour one dose of aspirin (50 mg to 325 mg daily) 
over another. Compared with aspirin, adjusted-dose 
warfarin reduces stroke by 39% (RRR; 95% CI, 22% 
to 52%) (Table 3) [21]. 
?
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Two randomized trials assessed the potential role 
of the combination of clopidogrel (75 mg daily) plus 
aspirin (75 mg to 100 mg daily) for preventing stroke 
in patients with atrial fi brillation. Th e Atrial fi brilla-
tion Clopidogrel Trial with Irbesartan for prevention 
of Vascular Events (ACTIVE) investigators compared 
this combination antiplatelet regimen with adjusted-
dose warfarin (target INR, 2.0 to 3.0) in patients with 
atrial fi brillation with 1 additional risk factor for stroke 
in ACTIVE W and found a 40% relative risk reduc-
tion (95% CI, 18% to 56%, P=0.001) for stroke with 
warfarin compared with the dual antiplatelet regimen. 
ACTIVE A compared clopidogrel combined with as-
pirin with aspirin alone in atrial fi brillation patients 
deemed unsuitable for warfarin anticoagulation and 
who had at least 1 additional risk factor for stroke (ap-
proximately 25% were deemed unsuitable because of 
concern for warfarin-associated bleeding). Dual anti-
platelet therapy resulted in a 28% relative risk reduc-
tion (95% CI, 17% to 38%; P=0.0002) in all strokes 
(including parenchymal ICH) over treatment with 
aspirin alone, but major bleeding was increased by 
57% (increase in RR; 95% CI, 29% to 92%, P<0.001); 
overall and in absolute terms, major vascular events 
(the study primary end point) were decreased 0.8% 
per year, but major haemorrhages increased 0.7% per 
year (RR for major vascular events and major haem-
orrhages, 0.97; 95% CI, 0.89 to 1.06; P=0.54). Dis-
abling/fatal stroke, however, was decreased by dual 
antiplatelet therapy (RRR, 26%; 95% CI, 11% to 38%; 
P=0.001) [21]. 
Th e initial 3 months of adjusted-dose warfarin are 
a particularly high-risk period for bleeding [25], and 
especially close monitoring of anticoagulation is ad-
vised during this interval.. Treatment of hypertension 
in atrial fi brillation patients reduces the risk of both 
ICH and ischemic stroke; hence, it has double ben-
efi ts for atrial fi brillation patients who have received 
anticoagulation. [26-28]. Target systolic blood pres-
sure should be <140 mm Hg. Th e benefi ts versus risks 
of the combined use of antiplatelet agents in addition 
to warfarin in elderly atrial fi brillation patients are in-
adequately defi ned. Combined use of warfarin with 
antiplatelet therapy increases the risk of intracranial 
and extracranial haemorrhage [29]. Adjusted-dose 
anticoagulation (target INR, 2.0 to 3.0) appears to of-
fer protection against MI that is comparable to aspirin 
in atrial fi brillation patients [30]. Addition of aspirin 
to warfarin is not recommended for most atrial fi bril-
lation patients with stable coronary artery disease. [31, 
32]. Clopidogrel plus aspirin combined with warfarin 
has been suggested for 9 to 12 months after placement 
of bare-metal coronary stents [33]. Because drug-
eluting stents require even more prolonged antiplate-
let therapy, bare-metal stents are generally preferred 
for atrial fi brillation patients taking warfarin [34]. A 
lower target INR of 2.0 to 2.5 has been recommended 
[35]. 
New treatment of atrial fi brillation
Direct thrombin inhibitors off er an alternative 
treatment with warfarin in patients with atrial fi brilla-
tion. In a international multicenter study of long-term 
anticoagulation treatment (RE-LY - Randomized 
Evaluation of Long-term Anticoagulation Th erapy) 
were enrolled 18,113 patients with atrial fi brillation 
who have had at least one additional risk factor for 
stroke Th e study demonstrated the ability of dab-
igatran to reduce the occurrence of both stroke and 
haemorrhage in patients who had atrial fi brillation 
with high risks of stroke compared with patients who 
received warfarin. RE-LY was designed to compare 








Estimated NNT for 
Primary Prevention
Adjusted-dose warfarin vs. control 6 2900 64 % (49–74) 40
Aspirin vs. control 7 3990 19 % (1–35) 140
Adjusted-dose warfarin vs. aspirin 9 4620 39 % (19–53) 90
CI indicates confi dence interval, and NNT, No. needed to treat. No. needed to treat for 1 y to prevent 1 stroke, based on a 3.5%/y stroke rate in 
untreated patients with atrial fi brillation and without prior stroke or TIA.
?
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2 fi xed doses (110mg or 150mg, twice daily) of dab-
igatran, each administered in a blinded manner, with 
open-label use of warfarin. In this study, in a popula-
tion of patients with atrial fi brillation, dabigatran at 
110 mg b.i.d was associated with stroke and systemic 
embolism rates similar to those associated with warfa-
rin, and with lower rates of major haemorrhage. How-
ever, when dabigatran was administered at a dose of 
150 mg, lower rates of stroke and systemic embolism 
and similar rates of major haemorrhage were found 
compared with warfarin [36]. Dabigatran has recently 
recognized by the Food and Drug Administration - 
FDA in the United States). In RE-LY, dabigatran 
demonstrated effi  cacy without the need for ongoing 
INR monitoring or dose adjustments. Furthermore, 
there were no food restrictions on those taking dab-
igatran in RE-LY. Th erefore dabigatran will off er pa-
tients and doctors the fi rst new treatment option for 
stroke prevention in atrial fi brillation in more than 50 
years. 
Table 4. Recommendations in primary stroke prevention in 
patients with nonvalvular atrial fi brillation [37] 
Recommendations
1. Active screening for atrial fi brillation in patients >65 
years of age in primary care settings using pulse taking fo-
llowed by an ECG as indicated can be useful (Class IIa; 
Level of Evidence B).
2. Adjusted-dose warfarin (target INR, 2.0 to 3.0) is re-
commended for all patients with nonvalvular atrial fi brilla-
tion deemed to be at high risk and many deemed to be at 
moderate risk for stroke who can receive it safely (Class I; 
Level of Evidence A). 
3. Antiplatelet therapy with aspirin is recommended for 
low-risk and some moderate-risk patients with atrial fi bri-
llation, based on patient preference, estimated bleeding risk 
if anticoagulated, and access to high-quality anticoagulati-
on monitoring (Class I; Level of Evidence A). 
4. For high-risk patients with atrial fi brillation deemed 
unsuitable for anticoagulation, dual antiplatelet therapy 
with clopidogrel and aspirin off ers more protection against 
stroke than aspirin alone but with increased risk of major 
bleeding and might be reasonable (Class IIb; Level of Evi-
dence B). 
5. Aggressive management of BP coupled with antithrom-
botic prophylaxis in elderly patients with atrial fi brillation 
can be useful (Class IIa; Level of Evidence B). 
Favourable preliminary results in the prevention of 
stroke in patients with atrial fi brillation also indicates 
the factor Xa inhibitor - rivaroxaban [38].
Recent changes to the guidelines for the man-
agement of stroke patients with atrial fi brillation are 
based on the results of the ACTIVE study. In the 
study arm ACTIVE A the combination of aspirin 
plus clopidogrel with aspirin alone were compared in 
patients who were not candidates for treatment with 
warfarin [21,22]. Th e results showed fewer ischemic 
strokes, but more bleedings in the treatment group 
with the combination compared with aspirin alone. 
Th e combination of these drugs brings the same risk 
of bleedings than warfarin and therefore is not recom-
mended for the patients who have a contraindication 
to warfarin because of bleeding risk [39]. 
Th e novelty in the recommendations is that pa-
tients with atrial fi brillation and at high risk of re-
stroke, who should temporarily break the oral anti-
coagulants, introduce a bridging therapy with low 
molecular weight heparin [39]. 
 
Tabela 5. Recommendations in secondary stroke prevention 
in patients with nonvalvular atrial fi brillation [39].
Recommendations
1. Adjusted-dose warfarin (target INR, 2.0 to 3.0) is re-
commended for all patients with stroke or TIA and with 
nonvalvular chronic or intermittent atrial fi brillation sho-
uld receive warfarin (Class I; Level of Evidence A).
2. Antiplatelet therapy with aspirin is recommended for 
some patients with atrial fi brillation with bleeding risk 
(Class I; Level of Evidence A).
3. Dual antiplatelet therapy with clopidogrel and aspirin 
off ers more protection against stroke than aspirin alone but 
with increased risk of major bleeding. Th e combination of 
these drugs brings the same risk of bleedings than warfa-
rin and therefore is not recommended for the patients who 
have a contraindication to warfarin because of bleeding risk 
(ClassIII; Level of Evidence B). New Recommendation!
4. Patients with atrial fi brillation and at high risk of re-
stroke (CHADS2 5 or 6), who should temporarily break 
the oral anticoagulants, introduce a bridging therapy with 
low molecular weight heparin (Class IIa; Level of Evidence 
C). New Recommendation! 
According the Canadian guidelines (Th e Cana-
dian Cardiovascular Society - CCS) dabigatran is 
recommended for the patients with atrial fi brillation 
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and at high risk for stroke because of its advantages 
over warfarin [40].
Conclusion
Atrial fi brillation is a major, prevalent, independent 
risk factor for ischemic stroke, and adjusted-dose war-
farin is highly effi  cacious for reducing stroke and death 
in high-risk patients with this condition. Adjusted-
dose warfarin continues to be underused, particularly 
among very elderly atrial fi brillation patients.
Development of safer, easier-to-use oral antico-
agulants might improve the benefi t-risk ratio. 
Novel oral anticoagulants (eg, direct thrombin 
inhibitors, factor Xa inhibitors) have and are being 
tested in several ongoing large randomized trials, and 
additional treatment options appear to be on the ho-
rizon.
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